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CRITICALLY APPRAISED TOPIC 
 
Title: Hippotherapy and gross motor function in children with spastic cerebral palsy: A critical 
analysis of the available literature 
 
Clinical Scenario: A seven-year old male presents with a primary diagnosis of spastic 
quadriplegic cerebral palsy (CP) while attending a school for children with disabilities in the 
township of Gugulethu, Cape Town, South Africa. Impairments include decreased trunk and 
pelvic control, decreased lower extremity strength, increased lower and upper extremity tone, 
an uncoordinated flexed gait pattern, and a lack of independent ambulation. Prior to the 
introduction of hippotherapy, the patient was non-ambulatory. Medical treatment to date has 
involved general trunk and lower extremity strengthening exercises, wheelchair positioning, 
speech and occupational therapy for speech and swallowing problems, and gait training. 
Hippotherapy is suggested to be an effective intervention for children with cerebral palsy to 
assist in neuromuscular re-education of postural muscles and decreasing postural tone and is 
currently being implemented as a routine intervention in the care of this patient.  
 
Brief introduction: CP is a non-progressive neurological disorder that results from a lesion to the 
developing cerebrum, either in utero, during the birthing process, or during the first years of life. 
There are two primary ways of classifying CP: region of the body that is affected and the type of 
CP. Affected areas include diplegia (upper extremities are affected to a greater extent than the 
lower extremities), hemiplegia (one side of the body is affected, involving both the upper and 
lower extremity), and quadriplegia (all four limbs and trunk are affected). Types of CP include 
spastic, dystonic, athetoid, ataxic, and mixed18. As the patient was diagnosed with spastic CP, 
the analysis will focus on this type. Spastic CP typically presents with increased tone in affected 
areas of the body with slow movements and resistance to movement. Management of CP varies 
depending on involvement of the disorder but can include stretching and strengthening of 
affected body parts, neuromuscular re-education, gait and balance training, botulinum toxin 
injections to hypertonic muscles, baclofen therapy, muscular release surgeries, and/or a 
selective dorsal rhizotomy procedure3.  
 
Clinically, CP is classified according to the Gross Motor Function Classification System (GMCFS). 
The GMFCS is a five-level classification system that describes children and youth with cerebral 
palsy according to self-initiated movements with an emphasis on sitting, walking, and wheeled 
mobility. Distinctions between levels are based on functional ability, the need for assistive 
technology, and quality of movement. The original version, published in 1997 by Palisano et al. 
describes children up to 24 months of age. An expanded version, the GMFCS E&R, was published 
and validated in 2008 by Palisano et al. to describe children and youth up to 18 years. Table 1 
highlights the general distinctions between levels of the GMFCS17. 
 
Table 1. General distinctions between levels of the GMFCS & GMFCS E&R
17
. 
Level Description 
I Walks without limitations 
II Walks with limitations 
III Walks using a hand-held mobility device 
IV Self-mobility with limitations; may use powered mobility 
V Transported in manual wheelchair 
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Hippotherapy and therapeutic horseback riding are the terms used to describe treatment 
strategies that utilize the movement of horse to improve postural control, balance, and general 
function and mobility. Hippotherapy is thought to be effective in managing patients with 
neurological disorders such as cerebral palsy because the pelvic movements of the horse are 
very similar, in biomechanical terms, to that of a human when walking4. By seating a patient on 
the horse’s back, the movement of the horse, including tempo, gait, and cadence, are thought 
to have a carry-over effect to the patient to help facilitate neuromuscular re-education to 
improve sitting balance and overall gross motor function. This occurs because these movements 
encourage bilateral postural muscle activation to react to the horse’s pelvic sway10. The body 
heat from the horse is also thought to improve blood circulation, which reduces abnormal 
muscle tone to aid in sitting balance14. 
 
While hippotherapy is growing in popularity as a treatment option for children with motor 
dysfunction secondary to CP, there is some controversy regarding the required time and costs as 
compared to other techniques11,12,13,15, such as whether a hippotherapy simulator can provide 
the same benefits as hippotherapy itself1,5,11,. The primary controversy lies in the often 
misinterpreted distinction between hippotherapy and therapeutic horseback riding (THR). THR 
refers to the use of horseback riding to teach equestrian skills to and provide recreational 
activities for individuals with disabilities, whereas hippotherapy refers to the implementation of 
specific, targeted exercises performed while riding the horse9. Proper hippotherapy requires 
additional training regarding human movement and physiology to implement exercises that 
address impairments, functional limitations, or participation restrictions of these individuals9. 
For the purposes of my clinical question, I want to critically appraise the highest quality available 
research regarding the efficacy of hippotherapy in improving gross motor function and balance 
in children with cerebral palsy.  
 
My Clinical question: Does physical therapy (PT) treatment involving hippotherapy lead to 
improved gross motor function and balance in children with cerebral palsy? 
 
Clinical Question PICO: 
 
Population – Children, ages 6-18 years, with spastic cerebral palsy (quadriplegia or 
diplegia) 
 
Intervention - Hippotherapy 
 
Comparison – Trunk and extremity strengthening and stretching exercises 
 
Outcome – Gross Motor Functional Measure (GMFM) 
 
Overall Clinical Bottom Line: Based on the results described by the authors identified in Table 2, 
there is low quality evidence supporting the use of hippotherapy as a gross motor 
function intervention for children with a primary diagnosis of cerebral palsy. Two studies 
were randomized-controlled trials while the other two utilized an A-B and A-B-A study 
design with moderate to poor internal validity. The large number of major threats to 
internal validity in all four articles dramatically decrease confidence in and ability to 
generalize findings from the study results. This suggests the need for more rigorous 
research with strict protocols and study design and larger, heterogeneous samples to 
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reach a definitive decision regarding the effectiveness of hippotherapy compared to 
strengthening and stretching exercises for the trunk and extremities in improving GMFM 
score as a measure of postural control. 
  
Search Terms:  Hippotherapy, dynamic postural exercise, equine-assisted therapy, physical 
therapy, therapeutic horseback riding, cerebral palsy 
 
Appraised By:   Joe Oelfke, SPT 
   School of Physical Therapy 
   College of Health Professions 
   Pacific University 
   Hillsboro, OR 97123 
   oelf7736@pacificu.edu  
 
Rationale for my chosen articles: 
Upon searching the PubMed database using the previously listed search terms, 43 articles were 
identified. Of these, four were selected that assessed the efficacy of hippotherapy for improving 
gross motor control in children with varying levels of involvement of spastic cerebral palsy. This 
selection was based primarily on how well the individual articles matched the clinical PICO 
based on my patient, followed by the quality of research design as measured by the PEDro 
score. Due to the lack of literature on this topic, three randomized-controlled trials and one 
quasiexperimental design trial were selected for this literature critique. These articles were 
selected based on their PEDro scores and most closely match the clinical PICO in terms of age 
and diagnosis for the children and the outcome measures employed. However, only Kang et al 
.article assessed hippotherapy in conjunction with traditional physical therapy as compared to 
physical therapy alone and a control. McGibbon et al. and Casady et al. utilized a repeated 
measures design. These two articles were selected as they provide evidence regarding the 
benefit of hippotherapy over a prolonged period of time. Finally, Herrero et al. assessed the 
efficacy of a hippotherapy simulator compared to barrel-sitting and the effect of each on gross 
motor function. Table 1 provides a brief summary of the clinical PICO and PEDro scores and 
Table 2 provides a comparison of the PEDro scores. 
 
  
Table 2. Brief summary of the PICO and PEDro scores of appraised articles. 
Author PEDro Score Population Intervention Comparison Outcome Measures 
Herrero et al. 
(2012) 
8/10 
38 children 
with CP 
Hippotherapy 
simulator 
Barrel sitting 
GMFM & 
SAS 
McGibbon et 
al. (2009) 
7/10* 
6 children with 
spastic CP 
Hippotherapy None 
GMFM & Self-
perception profiles 
Kang et al. 
(2012) 
5/10 
45 children 
with CP 
Hippotherapy 
Hippotherapy + 
PT and control 
Sitting balance test 
Casady et al. 
(2004) 
3/10 
10 children 
with CP 
Hippotherapy None GMFM & PEDI 
Note. Abbreviations: CP (cerebral palsy), PT (physical therapy), GMFM (Gross Motor Function Measure), SAS 
(Sitting Assessment Scale),  PEDI (Pediatric Evaluation of Disability Index).  
*PEDro score is not appropriate for entirety of study. More details are provided in the individual article appraisal. 
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Table 3. Comparison of PEDro Scores 
 Herrero, et 
al. 
McGibbon, et 
al.
 
Kang, et al.
 
Casady, et 
al. 
Random Y Y Y N 
Concealed allocation Y Y N N 
Baseline comparability Y Y Y Y 
Blind Subjects N N N N 
Blind Therapists N N N N 
Blind Assessors Y Y N N 
Adequate Follow-up Y Y Y N 
Intention-to-Treat Y N N Y 
Between Group Y Y Y N 
Point Estimates & 
Variability 
Y Y Y Y 
Total Score 8/10 7/10* 5/10 3/10 
*PEDro score is not appropriate for entirety of study. More details are provided in 
the individual article appraisal. 
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Article: Herrero P, Gomez-Trullen EM, Asensio A, et al. A. Study of the therapeutic effects of a 
hippotherapy simulator in children with cerebral palsy: A stratified single-blind randomized 
controlled trial. Clinical Rehabilitation, 2012; 1105-1113. 
 
Clinical Bottom Line: Based on the results of this article, treatment with a hippotherapy 
simulator does not appear to be an effective treatment for improving GMFM-66 score in 
children age 4-18 years with cerebral palsy. The treatment group received an individualized 
exercise program while sitting on a hippotherapy simulator for 15 minute treatment sessions, 
once per week for ten weeks. The control group received the same treatment protocol, but with 
the simulator switched off. The experimental group demonstrated a medium treatment effect 
for the SAS score [effect size = 0.59 (95% CI: -0.92 to 0.26)], but the 95% confidence interval 
crosses zero, suggesting that the true mean may actually favor the control group. In addition, 
the treatment group demonstrated a small treatment effect for the GMFM-66 score [effect size 
= 0.25 (95% CI: -0.10 to 0.60)], with the 95% confidence interval again crossing zero. When 
assessing dichotomous data, a number needed to treat of 9.5 (95% CI: 2.4 to -4.8) was 
calculated and when analyzing only the GMFCS level V patients, a number needed to harm of       
-2.81 (95% CI: 18.9 to -1.3) was calculated, indicating that the control group is more likely to 
improve; however, the confidence interval extends into infinity, thus creating a meaningless 
number. One minor and three major threats to internal validity were identified, dramatically 
decreasing confidence in the study results. While hippotherapy simulator treatment is a 
relatively low-cost, timely treatment option, poor internal and external validity of these results 
and feasibility issues suggest further research is necessary to reach a decision regarding the 
clinical PICO.  
 
Article PICO: 
 
 Population— 38 children, ages 4-18 years, with cerebral palsy 
 
Intervention— Hippotherapy simulator for 15 minute sessions, provided once per week 
for 10 weeks 
 
Comparison— Hippotherapy simulator turned off for 15 minute sessions, provided once 
per week for 10 weeks 
 
 Outcomes— GMFM and the Sitting Assessment Scale (SAS) 
 
Blinding: The authors state that this was a single-blind study in which the assessor was blinded 
to group allocation. Blinding of the subjects and therapists could not occur do to the nature of 
the study as it was readily apparent if the simulator was turned on or off. However, this is a 
minor threat to internal validity because, due to the children’s age and level of involvement of 
CP, they likely would not be capable of manipulating their performance to influence the 
outcomes of the study.  
 
Controls: The control group received the same 15 minute treatment sessions as the intervention 
group, once per week for 10 weeks, while sitting on the hippotherapy simulator; however, the 
simulator remained turned off for the duration of the treatment. As with the intervention group, 
the therapists also prescribed individualized therapeutic exercise during these sessions. This was 
an appropriate comparison group as the changes seen at completion of the study can most likely 
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be attributed to the rhythmic movements created by the simulator when turned on. However, 
as the therapists instructed the children to perform different motor activities according to their 
motor possibilities, there is the possibility that the individualized nature of the exercises could 
mean that observed differences between the groups may be inappropriately attributed to the 
intervention when in actuality they were due to an individualized treatment program. While 
there was an appropriate control group in this study, the methodology of treatment 
administration potentially threatens internal validity. 
 
Randomization: Assignment of subjects to groups was randomized and was stratified. The 
stratification was performed according to the GMFCS level, which was appropriate as it ensured 
a similar number of subjects were allocated to each group, at each GMFCS level. The 
randomization was also concealed and successful with no statistically significant differences at 
baseline (see Table 4); however the sample was biased toward a higher level of disability of 50% 
of the children classified as GMFCS level V. This can potentially impact interpretation of the 
results as the sample is not normally distributed. As a result, the sample sizes for each GMFCS 
level are too small to carry out a meaningful analysis and only the children with the highest level 
of disability can be appropriately analyzed. 
 
Table 4. Baseline comparability of groups, assuming an alpha level of 
0.05 to determine significance. 
Demographic & 
Outcome Measures 
Control Group 
Intervention 
Group 
P-
Value 
Mean Age 9.05 9.95 0.504 
Gender 10:9 14:5 0.179 
GMFCS Level I 2 2 0.834 
GMFCS Level II 2 1 - 
GMFCS Level III 3 2 - 
GMFCS Level IV 3 4 - 
GMFCS Level V 9 10 - 
Total GMFM Score 42.75 40.91 0.758 
GMFM Dimension B 29.84 25.68 0.405 
SAS Score 15.58 15.21 0.848 
Note. Table reflects the author's reported data. 
 
Study: This study was a single-blinded, stratified randomized-controlled trial with 19 subjects in 
both the control and intervention groups. The inclusion and exclusion criteria used were from a 
previously published study5. Subjects were included if they were between 4 and 18 years old 
with a primary diagnosis of CP. Subjects were excluded if they had undergone a selective dorsal 
rhizotomy, had active convulsions not controlled by medication, were allergic to electrode 
adhesives, had a visual impairment not corrected with glasses, had an associated illness or 
circumstance that may interfere with the results or be detrimental to treatment, or were unable 
to attend intervention sessions and/or refused to participate. 
 
After baseline measurements were taken by an independent assessor and sociodemographic 
information was obtained with a questionnaire, subjects were stratified into GMFCS levels as 
described above and then randomized into treatment and control groups. During the treatment 
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sessions, the children were placed on the hippotherapy simulator and were instructed to 
maintain the sitting position for 15 minutes. This included active extension of the trunk, 
stabilization of the pelvis, and abduction of the hips while the simulator produced a rhythmic 
and repetitive movement similar to the walking of a horse. During the 15 minutes sitting on the 
simulator, the therapist instructed the children to perform various activities that were 
individualized according to their motor possibilities. Treatment sessions for the control group 
were conducted in the same manner but with the simulator turned off. In this way, the control 
group received the same treatment without the rhythmic effects produced by the simulator. 
 
Outcome Measures: The outcome measures used in this study were the GMFM and the SAS, 
both of which are directly relevant to the clinical question. These outcome measures were 
assessed immediately following randomization and stratification, after the full 10 weeks of 
treatment, and after a three month follow-up. The reliability and validity of these outcome 
measures were not addressed in the study; however, previous studies have demonstrated high 
levels of inter- and intra-rater reliability6 and construct validity7. A minimal clinically important 
difference (MCID) of 0.8 on the GMFM-66 has been suggested16; however the population used 
in this calculation was ambulatory children. As the patient of interest was not ambulatory prior 
to the introduction of hippotherapy, this MCID is not valid for the clinical scenario. The authors 
also did not address clinimetric properties for the SAS. A previous study has cited excellent 
reliability values (p <.0.001) for the SAS8, but validity values and an MCID could not be located. 
 
Study Losses: Following randomization and group allocation four subjects dropped out from the 
study, three from the control group and one from the treatment group. Two of these dropouts 
occurred during the treatment sessions, and the other two occurred after the end of treatment 
prior to the three-month follow-up. However, all subjects were included in the data analysis in 
an intention-to-treat fashion with the previous data points being carried forward. All subjects 
were analyzed in the groups to which they were originally randomized. 
 
Summary of internal validity: One minor threat and three major threats to internal validity were 
identified in this study. The first threat is maturation; cerebral palsy is a non-progressive 
disorder which means that there is a possibility that any changes seen from the pre-test to the 
three-month follow-up could be due to natural history of the disorder. Because both groups 
received treatment, improvements in outcome measure scores cannot necessarily be the direct 
result of the hippotherapy simulator. This, however, is a minor threat as three months is a 
relatively short time to see significant changes in function in children with CP across the GMFCS 
levels. The second threat is in study design and reliability of treatment implementation; 
although not possible in this study, the therapists were not blinded to group allocation. This may 
inherently result in bias in perceived treatment potential, possibly affecting the therapy 
provided as it was on an individualized basis rather than a standardized protocol. This is a major 
threat because as there was no true control group that received no treatment. Differences in 
individualized therapy provided between groups may have a significant effect on the outcome of 
the study and result in an incorrect interpretation of observed differences between groups as 
they may be attributed to the intervention when in actuality they were due to the individualized 
program. The third threat is the possibility of inadequate power. The authors do not state how 
the sample size of 38 subjects was established nor did they perform a power analysis, suggesting 
that there is a strong possibility that an adequate sample size was not obtained. This is a major 
threat because it can result in either a Type I (observing statistical significance when in fact it 
does not exist) or Type II (no statistical significance is observed when in fact it does exist) error 
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and can affect the interpretation of statistical outcomes. The fourth threat is inter-subject 
differences at baseline. The authors state that the groups were similar at baseline, however 
following stratification the sample was heavily biased toward children with higher levels of 
disability; 19 children (50% of the sample) were classified as GMFCS level V. This is a major 
threat because if there is not a normal distribution of patient presentation across the sample, it 
can affect the sensitivity of statistical tests to demonstrate true changes over time. Overall, this 
article has poor internal validity, dramatically decreasing confidence in the study results. 
 
Evidence: Both outcome measures are relevant to the clinical question. However, the results of 
the SAS are not helpful to the clinical question as it was largely insensitive to changes over the 
treatment and follow-up periods. The authors focused primarily on dimension B of the GMFM 
(sitting); however, because the patient of interest had deficits in more functional areas than 
sitting, the analysis will include the full GMFM score. In addition, as the patient of interest was 
being treated with hippotherapy for a full year, this analysis will focus on the long-term effect of 
hippotherapy (baseline vs. three-month follow-up). Results for the GMFCS level V subgroup will 
also be analyzed due to the sample bias. The following tables include data reported by Herrero 
et al.; effect sizes were calculated by the appraisal author based on mean differences from 
baseline to three-month follow-up at the conclusion of the study, as the authors did not report 
statistical significance for any of the observed differences. As an appropriate MCID could not be 
located, lacking identification of statistical significance limits the ability to interpret the clinical 
relevance of any observed treatment effects, regardless of the effect size. 
 
Table 5. Results of the SAS for the entire sample (n=38). 
Group (n) 
Baseline 
Mean (SD) 
3-Month 
Follow-Up 
Mean (SD) 
Mean 
Difference (SD) 
Effect Size  
(95% Confidence Interval) 
Within-Group Between-Group 
Experimental (19) 15.21 (5.93) 15.00 (5.82) -0.21 (0.92) 0.72 0.59 (-0.06 to 
1.24) Control (19) 15.58 (5.81) 15.84 (5.70) 0.26 (0.65) 0.72 
 
According to the above calculations, the change in SAS score from baseline to follow-up for both 
groups correlates with a medium effect size.  Additionally, between-group comparison reveals a 
medium effect size in favor of the experimental group. However, the 95% confidence interval 
crosses zero, suggesting the true mean may actually favor the control group rather than the 
experimental group, although this is somewhat unlikely given that the low end of the confidence 
interval is -0.06. The authors do not report if the baseline to three-month follow-up changes 
were clinically significant, so definitive and clinically meaningful conclusions from the within-
group effect sizes cannot be made. 
 
Table 6. Results of the SAS for GMFCS level V (n=19).   
Group (n) 
Baseline Mean 
(SD) 
3-Month 
Follow-Up 
Mean (SD) 
Mean 
Difference (SD) 
Effect Size  
(95% Confidence Interval) 
Within-Group Between-Group 
Experimental (10) 11.56 (5.90) 11.11 (5.30) -0.4 (1.33) 0.63 0.74 (-0.19 to 
1.67) Control (9) 11.00 (5.52) 11.44 (5.63) 0.44 (0.88) 0.63 
 
 9
According to the above calculations, the change in SAS score from baseline to follow-up for the 
GMFCS level V subgroup correlates with a medium within-group effect size for both groups and 
a medium between-group effect size in favor of the experimental group. The 95% confidence 
interval also crosses zero, suggesting that the true mean may actually favor the control group 
rather than the experimental group. In addition, the authors do not report if the baseline to 
three-month follow-up changes were clinically significant, so definitive and meaningful 
conclusions from the within-group effect sizes cannot be made. 
 
Table 7. Results of the GMFM-66 for the entire sample (n=38). 
Group (n) 
Baseline Mean 
(SD) 
3-Month 
Follow-Up 
Mean (SD) 
Mean 
Difference 
(SD) 
Effect Size  
(95% Confidence Interval) 
Within-Group Between-Group 
Experimental (19) 40.91 (17.50) 43.53 (17.16) 2.63 (5.75) 0.20 
0.25 (-0.39 to 0.89) 
Control (19) 42.75 (19.02) 44.24 (19.76) 1.50 (2.78) 0.20 
 
According to the calculations presented in Table 7, the change in GMFM-66 scores for the entire 
sample correlates with a small within-group effect sizes for both groups and a small between-
group effect size in favor of the experimental group. However, the confidence interval again 
crosses zero, decreasing the ability to draw any definitive conclusions from this data. In addition, 
the authors do not report if the baseline to three-month follow-up changes were significant, so 
definitive and meaningful conclusions from the within-group effect sizes cannot be made. 
 
Table 8. Results of the GMFM-66 for GMFCS level V (n=19).   
Group 
Baseline Mean 
(SD) 
3-Month 
Follow-Up 
Mean (SD) 
Mean 
Difference 
(SD) 
Effect Size  
(95% Confidence Interval) 
Within-Group Between-Group 
Experimental (10) 28.43 (12.07) 31.11 (8.12) 2.68 (7.25) 0.33 0.42 (-0.49 to 
1.33) Control (9) 28.14 (14.68) 28.46 (13.82) 0.32 (2.70) 0.33 
 
According to the calculations presented in Table 8, the change in GMFM-66 for the GMFCS level 
V subgroup correlates with small within-group effect sizes for both groups and a small between-
group effect size in favor of the experimental group. The 95% confidence interval again crosses 
zero, and the authors do not report if the baseline to three-month follow-up changes were 
significant. As a result, definitive and meaningful conclusions from the within-group effect sizes 
cannot be made. 
 
Table 9. Number of subjects (n=38) who improved at follow-up in the total GMFM-66 score. 
Improvement from baseline 
Yes No Total 
Group 
Experimental 10 9 19 
Control 12 7 19 
Total 22 16 38 
 
Herrero et al. defined 'improvement from baseline' as an improvement in score on the GMFM-
66 total score, but does not take into consideration statistical or clinical significance associated 
with those changes. Using the data presented in Table 7, the calculated number needed to treat 
(NNT) is 9.5 (95% CI: 2.4 to -4.8). This suggests that 10 patients would need to be treated with 
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the hippotherapy simulator in order to see one patient improve on the GMFM-66 total score. 
While the effect size associated with this data demonstrated a medium positive between-group 
effect of 0.71 (see Table 7), the 95% confidence interval crosses zero at the upper limit, 
suggesting that the NNT may be as high as infinity. Again, no definitive conclusions can be drawn 
from this data due to the confidence interval and no clinical correlation of 'improvement' on the 
GMFM-66.  
 
Table 10. Number of subjects (n=19) who improved on the GMFM-66 at follow-up in the GMFCS level V 
subgroup. 
Improvement from baseline  
Yes No Total  
Group 
Experimental 8 2 10  
Control 4 5 9  
Total 12 7 19  
 
Based on the data presented in Table 8, the calculated number needed to harm (NNH) is 2.81 
(95% CI: 18.9 to -1.3). Calculating a NNH suggests that three people would need to be treated 
with the control in order to see one improvement, again suggesting that the control may 
actually be more beneficial than the intervention. While the effect sizes associated with this 
data demonstrate a small within-group effect of 0.22 (see Table 8), the 95% CI again crosses 
zero at the upper limit, suggesting that the NNH  may be as high as infinity. As discussed 
previously, no definitive conclusions can be drawn from this data. 
 
Applicability of study results: 
 
Benefits vs. Costs: Based on the results of this study, few benefits were identified. Time 
commitment for both the patient and therapist is very minimal as treatment sessions lasted only 
15 minutes and were conducted once per week. No adverse events were reported. The 
equipment used in this study was the Core Trainer Exercise Equipment, JOBA produced by 
Panasonic. The cost of this specific device could not be located, however similar equipment 
costs $220-250, which does not present a significant financial burden on a facility. 
 
Despite the low cost for a single hippotherapy simulator, the minimum purchase order for 
similar equipment as used in this study is 45 units and as a result presents a significant financial 
and feasibility issue for a facility.  Training for proper operation the various settings of the device 
is also required of the therapist. In addition, while both groups received the same amount of 
intervention time and resources, neither demonstrated a significant change from baseline in 
either the SAS or GMFM-66 scores at conclusion of the study, as evidenced by previously 
reported effect sizes.  
 
For these reasons, and the lack of significant benefit for the patients, the additional financial and 
time costs for a hippotherapy simulator are not justified.  
 
Feasibility of treatment: The procedures used in this study were not described sufficiently for 
reproduction, although a previous study by the same authors outlined the equipment settings 
used during treatment5. In addition, the individualized exercises taught to the children were not 
described, so this could not be replicated. The requirements of equipment, expertise, and time, 
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however, would be readily available in a clinical setting. The treatment is pain-free and 
adherence to a home exercise program (HEP) is not required. Ten treatment sessions is 
reasonable for a plan of care and is also likely within what is allowed by insurance companies, 
especially for children in a school district setting who are typically seen at least once per week 
for the full school year. However, as the presented data indicates, hippotherapy simulator 
treatment does not appear to be an effective treatment for children with cerebral palsy, which 
creates a large feasibility issue for the therapist, patient, and insurer.  
 
Summary of external validity: While this study matches the clinical PICO very well in terms of 
age and diagnosis, it compares a hippotherapy simulator (versus true hippotherapy) with an 
individualized exercise program to barrel-sitting with the same individualized exercise program. 
A direct comparison of true hippotherapy to “traditional” physical therapy treatment (e.g. 
stretching and strengthening exercises) for CP would be more beneficial to make an informed 
clinical decision regarding the usefulness and effectiveness of hippotherapy. In addition, the 
threats to internal validity compromise the ability to generalize these results to a clinical setting 
due to a potentially inappropriate sample size, study design and reliability of treatment 
intervention, and uneven distribution of patient presentation in the two groups. However, the 
sample is similar to patients treated in a school district for children with CP. 
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Article: McGibbon NH, Benda W, Duncan BR, Silkwood-Sherer D. Immediate and long-term 
effects of hippotherapy on symmetry of adductor muscle activity and functional ability in 
children with spastic cerebral palsy. Archives of Physical Medicine and Rehabilitation, 2009; 966-
974. 
 
Clinical Bottom Line: Based on the results of this article, hippotherapy intervention appears to 
be an effective treatment for improving GMFM-66 score in children age 4-16 years with a 
primary diagnosis of spastic CP, although the high number of threats to internal validity 
dramatically compromises the results of this study and the ability to make definitive 
conclusions. This study utilized an A-B design with no control group, therefore changes observed 
at the conclusion of the study cannot be directly attributed to the intervention. Statistical 
analysis with a Friedman test and Nemenyi's post-hoc test demonstrated significant differences 
between T3, T4, and both baseline measures (Χ2-calculated = 14.6, Χ2-critical = 7.82, p<0.05). 
One minor and six major threats to internal validity were identified, drastically decreasing 
confidence in the study results and compromising external validity. While hippotherapy appears 
to be an effective and timely intervention, very poor internal and external validity of these 
results as well as feasibility issues and a high amount of additional training required of the 
therapist suggest that further, higher quality research is necessary to reach a decision regarding 
the potential benefits of hippotherapy.   
 
Article PICO: 
 
 Population— Six children with a diagnosis of spastic CP, age 4-16 years 
 
 Intervention— 30-minute hippotherapy sessions, delivered once per week for 12 weeks 
 
 Comparison— Baseline GMFM-66 measurements 
 
 Outcomes— GMFM-66, adductor muscle activity measured via surface 
electromyography (EMG), the Self-Perception Profile for Children, ages 8 to 13, and the 
Pictorial Self-Perception Profile for Young children, ages 4 to 7 
 
Blinding: As the authors utilized an A-B-A design where the subjects served as their own control, 
blinding of the subjects, therapists, and assessors was not possible. This, however, is not a 
significant threat as the children likely were not able to manipulate their performance to 
influence the results of the study. In addition, as there was no true comparison group, therapist 
administration of the treatment and assessor evaluation of the treatment effect would not have 
a significant effect on the study outcome. 
 
Controls:  There was no true control group in this study and the six subjects served as their own 
control. This was not an appropriate comparison group because the observed differences 
between groups cannot be attributed to the intervention as there is a large risk of maturation 
due to the long time periods between assessment sessions.  
 
Randomization: Randomization did not occur in the second, long-term portion of the study, 
described below.  To establish the study sample, the authors recruited the first six participants 
from the first phase to respond and who met the eligibility criteria. 
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Study: The study was a pretest/posttest randomized controlled trial conducted at an outpatient 
hippotherapy center accredited by the North American Riding for the Handicapped Association 
(now the Professional Association of Therapeutic Horsemanship International [PATHI]) and was 
conducted under the direction and supervision of a physical therapist certified as a 
Hippotherapy Clinical Specialist by the American Hippotherapy Certification Board. This study 
was divided into two phases. Phase I investigated the immediate effects of 10-minutes of 
hippotherapy on symmetry of adductor muscle activity and functional ability in children with 
spastic cerebral palsy. Phase II investigated the long-term effects of 12 weeks of weekly 30-
minute hippotherapy treatment sessions on adductor activity, self-concept, and gross motor 
function. Only Phase II is applicable to the clinical scenario, and thus is the only portion that will 
be analyzed by the appraisal author. To determine the population for Phase II, the authors 
enrolled the first six children from Phase I who agreed to the study conditions and met the 
eligibility criteria. Inclusion criteria were as follows: diagnosis of spastic CP made by a pediatric 
neurologist, age 4-16 years, ability to walk independently with or without an assistive device, 
ability to comply with the study protocol and follow verbal directions, and sufficient hip 
abduction to sit astride a horse or barrel with no evidence or report of hip dislocation. Exclusion 
criteria were as follows: previous history of selective dorsal rhizotomy, tonic clonic seizures 
uncontrolled by medication, known allergy to horses, dust, or electrode adhesive, surgical 
procedures, botox injections, lower extremity casting within six months prior to testing, and 
hippotherapy or horseback riding experience within six months prior to testing. Participants 
were also required to obtain a complete physician’s referral and evaluation prior to participation 
in the 12 weeks of treatment. 
 
Phase II was a 36-week repeated-measures design divided into three 12-week sections: baseline, 
treatment, and post-treatment. No intervention was provided on the baseline and post-
treatment days. All children were assessed on four separate occasions throughout the 36-week 
period: T1 (EMG data for Phase I marked the beginning), T2 (12 weeks later immediately prior to 
the start of treatment), T3 (immediately after completion of 12 weeks of treatment), and T4 (12 
weeks after termination of treatment). Figure 1 provides a graphic representation of the 
assessment scheme. All six children received one weekly session of hippotherapy during the 
treatment period.  
 
Figure 1. Phase II assessment intervals. 
T1 Baseline T2 Treatment T3 
Post-
treatment T4 
12 weeks 12 weeks 12 weeks 
Note: T=test. 
 
The treatment sessions followed a previously published protocol19, which was modified to 
address each child’s treatment goals. Sessions began with an initial warm-up in which the child 
was placed on the horse and became relaxed and adjusted to the rhythmic movement of the 
horse’s pelvis and maintaining balance during a dynamic centered sitting position. Once the 
warm-up was completed, the horse began to walk in straight lines and at gentle curves while the 
child maintained a central seated position on the horse’s back. The challenge to the child was 
gradually increased via modifications to the horse’s movement and walking patterns: 
introduction of figure eights, circles, or serpentines challenge lateral weight shift and midline 
postural control whereas lengthening the stride of the horse transmits greater movement 
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amplitude through the child’s pelvis and acceleration/deceleration of walking speed challenges 
anticipatory postural reactions3. Specific exercises were also incorporated into the horseback 
riding as appropriate. These exercises included changing position on the horse, core stability, 
and motor planning (i.e. backward sitting, supine to sit, trunk rotation, and side sitting). As the 
study progressed, a few children were able to use a saddle and stirrups to facilitate lower 
extremity strengthening, midrange segmental control, and coordination with exercises such as 
partial stand in the stirrups and a sit-stand-sit sequence. The sessions concluded with a short 
cool-down phase as needed, but detail of the cool-down process was not detailed by the 
authors. 
 
Outcome Measures: The outcome measures used in this study included adductor muscle activity 
using surface EMG, the GMFM-66, the Self-Perception Profile for Children, ages 8 to 13, and the 
Pictorial Self-Perception Profile for Young Children, ages 4 to 7. However, the only outcome 
measure of interest to help answer the clinical question is the GMFM-66. Clinimetric 
characteristics of this measure are as previously discussed. The reported MCID of 0.8 was 
calculated using ambulatory children16, and will be used for data analysis as all participants in 
this study were ambulatory. However, as the patient of interest was not ambulatory prior to the 
introduction of hippotherapy, the ability to make draw meaningful conclusions from the results 
will be limited. 
 
Study Losses: This study did not experience any losses. All subjects completed assessment at 
each testing period. 
 
Summary of internal validity: Seven major threats to internal validity were identified in this 
study. The first threat is maturation. Due to the duration of the study (36 weeks) there is a 
possibility that, because CP is a non-progressive disorder, any observed differences at the post-
treatment testing period may be due to natural history of the disorder rather than the 
intervention and that these children would have improved regardless of treatment. The authors 
did not account for this threat by using a control group. The second threat is selection bias as 
randomization in selection of participants from the entire sample from Phase I did not occur. 
Because the authors enrolled the first six children who agreed to the study conditions and met 
inclusion criteria, there is a strong possibility that these six children were not a heterogeneous 
sample and did not accurately represent children with spastic CP as a whole. The third is the 
threat of repeated testing. The children in this study were tested four times during Phase II and 
as a result, may have become familiar with the GMFM-66, leading to improved scores 
independent of treatment effect. Because cerebral palsy can present with or without cognitive 
impairments, this is a major threat. The fourth threat to internal validity is inadequate power. A 
power analysis was performed for Phase I of this study; however, a repeat power analysis was 
not performed for Phase II and, as a result, the Phase II sample size is very low. This is a major 
threat because without a power analysis an appropriate sample size cannot be determined, 
which can result in a Type I or Type II error as previously discussed. The fifth threat is rater bias. 
Due to the A-B study design, blinding of the assessors was not possible and creates the 
possibility that the rater could subconsciously alter the GMFM-66 score given to the children 
based on the desire to see improvement at the T4 testing session. The sixth threat is 
inappropriate statistical tests. The authors do not state how the results of the GMFM-66 were 
analyzed to determine significance of observed changes, and do not provide the results of 
statistical tests ran on the data set. This is also a major threat because meaningful conclusions 
cannot be determined without statistical evidence of relevant observed differences. The 
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seventh threat is lack of a strict protocol. While the hippotherapy treatment sessions followed a 
similar overall pattern (warm-up, straight-line walking, curved walking, figure eights, cool-
down), the authors incorporated individualized therapeutic exercises during horse-back riding as 
appropriate for the child. As a result, there is the possibility that any observed differences are 
inappropriately attributed to the intervention when in actuality they were due to an 
individualized program. In addition, the PEDro score given for the entirety of this study is not 
appropriate for Phase II on its own due to the large number of internal validity threats. Overall, 
Phase II of this study has poor internal validity, dramatically decreasing confidence in study 
results. 
  
Evidence: Three outcome measures were utilized by the authors in Phase II of this study, but as 
stated previously only the GMFM-66 outcomes are relevant to the clinical question. As such, this 
appraisal will focus on the two assessment intervals: T1-T2 to determine baseline consistency, 
and T1-T4 to highlight the long-term effect of hippotherapy on gross motor function. As the 
patient of interest was being treated for a full year of hippotherapy, this long-term effect is most 
relevant to the clinical scenario. All statistical calculations were completed by the appraisal 
author based on the provided individual data by McGibbon et al. Table 11 highlights the 
individual GMFM-66 scores at each testing interval used in the data analysis. 
 
Table 11. Phase II GMFM-66 scores at each interval,  
as presented by McGibbon et al. 
Subject T1 T2 T3 T4  
1 56.62 56.86 63.33 65.33  
2 51.85 50.62 54.38 53.62  
3 47.68 47.09 50.62 52.62  
4 65.63 65.33 70.39 68.86  
5 58.56 59.86 63.63 64.98  
6 44.31 46.32 49.21 50.09  
 
Prior to carrying out any data analysis, the score data highlighted in Table 11 must be converted 
to rank data. Because the subjects in Phase II were not allocated in a randomized fashion, the 
small sample size, and the potential lack of a normally distributed sample, analyzing the data 
using a one-way ANOVA would violate the inherent requirements for use of such tests. As a 
result, a within-group analysis utilizing the Friedman test will be used for data analysis. Table 12 
highlights the Phase II GMFM-66 scores converted to rank data for use in the analysis. 
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Table 12. Phase II GMFM-66 scores at each interval, adjusted for rank order analysis using a Friedman 
test. Rank Differences were determined with a Nemenyi's Post-Hoc Test. 
Subject T1 T1 - Rank T2 T2 - Rank T3 T3 - Rank T4 T4 - Rank 
1 56.62 1 56.86 2 63.33 3 65.33 4 
2 51.85 2 50.62 1 54.38 4 53.62 3 
3 47.68 2 47.09 1 50.62 3 52.62 4 
4 65.63 2 65.33 1 70.39 4 68.86 3 
5 58.56 1 59.86 2 63.63 3 64.98 4 
6 44.31 1 46.32 2 49.21 3 50.09 4 
Rank 
Differences 
  9   9   20   22 
 
Results of the Friedman test demonstrated a Χ2-calculated value of 14.6 and a Χ2-critical value of 
14.6, which suggests that a significant difference in GMFM-66 mean score exists between the 
four time intervals at an alpha level of 0.05. To determine where significant differences exist 
within the data set, a Nemenyi's Post-Hoc Test was used, which yielded rank differences 
highlighted in Table 12. Post-hoc testing also demonstrated a critical value of 12.5, indicating 
that any rank differences greater than this value are significant at an alpha level of 0.05. 
 
The sample baseline GMFM-66 scores did not change from T1 to T2 (rank difference = 9; 
p>0.05). However, significant differences were observed between T3 and T4 (rank difference = 
20 and 22, respectively; p<0.05), and T3 and T4 were significantly different from the two 
baseline intervals. The results of this analysis suggest that hippotherapy resulted in 
improvement in GMFM-66 score from baseline to immediate cessation of treatment, and from 
both those intervals to the 12-week follow-up following cessation of treatment.  
 
Applicability of study results: 
 
Benefits vs. Costs: Following the appraisal of this study, few benefits were identified. Time 
commitment for the therapist, child, and child's family is relatively low as treatment sessions 
were 30 minutes in duration. No adverse events were reported. While these benefits are 
supported by significant decrease in GMFM-66 scores from baseline to T4, the number of 
threats to internal validity suggests that the benefits are not justified when considering the costs 
and other potential treatment options. All participants received the same amount of treatment 
time and direct time with the therapist. 
 
While there are over 850 certified hippotherapy centers around the world, availability of a 
center largely varies based on geographic location will affect feasibility of treatment. For 
example, over 100 locations exist within the United States, but there is only one PATHI-certified 
center in Canada25. Additional training by the therapist is also required, including a board 
certification to become a credentialed hippotherapy instructor, which is potentially a large 
barrier preventing access to appropriate hippotherapy treatment. In addition, while the groups 
received the same total time with a therapist and number of treatment sessions, the 
individualized nature of therapeutic exercise prescription compromises the ability to make 
definitive decisions regarding the reported outcomes of the study. 
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For these reasons and the large number of threats to internal validity, the additional costs and 
feasibility issues regarding implementation of hippotherapy do not appear to be justified. 
  
Feasibility of treatment: The procedures utilized in this study are described sufficiently for 
reproduction, including the primary individualized therapeutic exercises used during 
hippotherapy sessions. The requirements of equipment (access to a PATHI-certified center and 
clinical specialization) are likely not readily available in a clinical setting; however, the duration 
of hippotherapy sessions are within the timeframe allowed by most insurance and physical 
therapy companies. This is especially relevant for a school-district setting where children are 
typically seen once per week for a full year. Treatment was reported to be pain-free and 
adherence to an HEP was not required. However, the large number of threats to internal validity 
compromises the ability to make clinical decisions based on the outcome of this study, which 
creates a large feasibility issue for the patient, therapist, and insurer. 
 
Summary of external validity: While this study matches the clinical PICO very well in terms of 
patient age, primary diagnosis, both length and type of intervention, and typical population seen 
in a school district for children with CP, it utilizes an A-B study design. The lack of a true control 
group and comparison to "traditional" physical therapy intervention in conjunction with the 
large number of major threats to internal validity further limit the ability to make informed 
clinical decisions regarding the efficacy of hippotherapy over other treatment options and ability 
to extrapolate the results to other populations or types of CP. 
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Article:  Kang H, Jung J, Yu J. Effects of hippotherapy on the sitting balance of children with 
cerebral palsy: a randomized controlled trial. Journal of Physical Therapy Science, 2012; 833-836. 
 
Clinical Bottom Line: Based on the results of this article, hippotherapy plus traditional physical 
therapy appears to be an effective and safe treatment option to improve sitting balance in 
children age 6-10 years with a primary diagnosis of severe hemiplegic or diplegic CP. However, 
one minor and four major threats to internal validity, as well as poor feasibility, reduce 
confidence in and generalizability of the results.  
This study was a randomized controlled trial where the both the hippotherapy and physical 
therapy group received traditional stretching and strengthening exercises for 30 minute 
sessions, semi-weekly, for eight weeks. The hippotherapy group additionally received physical 
therapy treatment on the same schedule, and the control group received no intervention. 
Statistical analysis demonstrated that, while the physical therapy group improved in sitting 
balance from pre- to post-treatment (p < 0.05, effect size range: 0.04 - 0.13), the hippotherapy 
group demonstrated much larger effect sizes for the same time frame (p <0.05, effect size 
range: 0.92 - 1.17). The hippotherapy group also demonstrated large between-group effect sizes 
that favor hippotherapy over physical therapy or control (p < 0.05, effect size range: 0.37 - 2.07).   
While hippotherapy plus traditional physical therapy appears to be an effective and timely 
intervention, internal and external validity and feasibility issues suggest that further research is 
necessary to reach a decision regarding the clinical PICO. Future research should include a more 
strict study protocol and design and larger sample size to reduce the threats to internal validity. 
Article PICO: 
 
 Population— 45 children with hemiplegic or diplegic CP, age 6-10 years 
 
 Intervention— Hippotherapy plus physical therapy (HTG) 
 
 Comparison— Physical therapy (PTG) and no intervention (CON) 
 
 Outcomes— Sitting balance as measured by center of pressure sway on a force plate 
 
Blinding: Blinding of the therapists to group allocation was not possible due to the nature of this 
study; it was readily apparent to which group participants were allocated. However, subject 
blinding was utilized as participants in the HTG and PTG groups were kept separate at all times. 
The HTG received treatment in the morning while the PTG received treatment in the afternoon, 
and participants were forbidden to speak with one another regarding the treatment and study. 
The authors do not state whether the assessor was blinded to group allocation. This is a 
potentially significant threat as the assessor may either intentionally or unintentionally favor 
one group over another.  
 
Controls:  There were two comparison groups in this study: PTG, which only received physical 
therapy, and CON, which received no treatment. These both were appropriate comparison 
 19
groups as the sole difference between HTG, PTG, and CON was the type of intervention applied, 
meaning differences between groups can most likely be attributed to the intervention.  
 
Randomization: Participants were randomly assigned to the three groups using a table of 
random sampling numbers. The authors do not state whether or not randomization was 
concealed; however, randomization was successful as the authors report no statistical 
differences in any variables between groups prior to therapy. As the subjects included in this 
study had either hemiplegic or diplegic CP, randomization should have been stratified due to the 
significant differences in motor ability between these two populations. 
 
Study: This was a single-blind randomized controlled trial with a total of 45 participants in three 
groups, carried out by the K equestrian team and staff from S hospital in Korea. Following 
explanation of the study and obtaining consent, participants were allocated to one of three 
groups (HTG, PTG, and CON) as stated previously. Inclusion and exclusion criteria were as 
follows: independent gait ability of less than 10 minutes, no horse riding-related experience in 
previous two years, no internal or neurological surgery in previous two months, and no specific 
medical problems including psychological problems.  
 
Following randomization, a baseline sitting balance was assessed using a force plate placed on a 
wooden box. Subjects sat in the center of the force plate and were asked to look at a 10 cm 
diameter circle placed one meter ahead. The center of upper body weight was traced for 30 
seconds for three repetitions with rest allowed to relieve fatigue. Following baseline 
assessment, the HTG and PTG were provided with traditional physical therapy comprised of 
strengthening and stretching exercises for 30-minute sessions, semi-weekly for eight weeks. This 
treatment was performed by two expert physical therapists but was not described further. The 
HTG also received hippotherapy, in which a leader pulled the reins of a horse at the front and 
two side-walkers held the legs of the children to prevent them from falling. The hippotherapy 
consisted of sitting and standing in the saddle, manipulating objects such as a bar, ball, ring, and 
toy, and maintaining posture while the horse moves. No other specific exercises or protocol was 
provided. The CON received no treatment. 
 
Following eight weeks of intervention, a post-test was performed and the results were analyzed 
utilizing a paired t-test to assess within-group differences in sitting balance from baseline to 
post-treatment and a one-way ANOVA to determine between-group differences from baseline 
to post-treatment. Post-hoc calculations were performed using the Bonferroni correction, and 
statistical significance for all tests was accepted with an alpha-value of 0.05. 
 
Outcome Measures: While not directly relevant to gross motor function, the only outcome 
measure utilized in this study is sitting balance as measured by center of pressure excursion on a 
force plate. Reliability and validity was not addressed by the authors, and an MCID was not 
provided. However, these clinimetric properties have been determined in previous studies. 
Kyvelidou et al. (2012) found that center of pressure excursion measurements on a force plate 
system demonstrated high intra- and inter-session intraclass correlation coefficients (ICC), and 
these reliability values increased as sitting posture improved20. In addition, center of pressure 
excursion has been found to be sensitive in discernment of balance performance in children 
with cerebral palsy21-24. It would also appear this method of quantifying sitting balance has face 
validity as any change in center of pressure excursion while sitting on a force plate would be the 
direct result of postural sway. 
 20
Study Losses: One child each in the HTG and CON withdrew from the study prior to post-
treatment assessment; however, no further details were reported regarding the reasons for 
withdrawal. However, all subjects were analyzed in the groups to which they were randomized 
and an intention-to-treat analysis was not indicated as study losses totaled less than 15% of 
both the total sample size and individual group sample sizes. 
 
Summary of internal validity: One minor threat and three major threats to internal validity were 
identified in this study. The first threat is extraneous variables, such as patient motivation or 
activities outside of the experimental treatment sessions. This is a minor threat, however; as the 
study population was comprised of severe CP, extra-experimental activities likely would not 
cause a large effect on sitting balance in this population. The second threat is rater bias. This is a 
major threat, as a lack of blinding of the assessors can cause a subconscious tendency to favor 
the HTG over PTG and CON. The second major threat is a lack of statistical power. The authors 
do not state if a power analysis was performed prior to randomization of subjects and data 
collection, and an insufficient sample size has the potential to cause a Type I or Type II error, as 
described previously. The third major threat is the Hawthorne Effect. Participants tend to act 
differently when they know they are being studied and may exhibit a change in baseline to post-
treatment outcome measure scores simply due to interaction with a therapist or researcher. As 
it is not clear if all groups received the same amount of treatment time or if CON had direct 
interaction with a researcher, there is the possibility that observed treatment effects could be 
due to differences in direct interaction with a clinician or researcher. Overall, this study has poor 
internal validity, dramatically decreasing confidence in the study results. 
 
Evidence: The only outcome measure used in this study is sitting balance as measured by center 
of pressure excursion and velocity on a force plate. While this is not a direct measure of gross 
motor function, there is a sitting component of the GMFM and as such, this outcome measure is 
considered relevant to the clinical scenario. Significant differences between groups that are 
identified below were calculated by the study authors. All effect size calculations were 
performed by the appraisal author.  
 
Table 13. Excursion and velocity of excursion data for each group, from pre-test to post-test. Data represented as group mean ± 
standard deviation. 
Item Direction 
Pre-test   Post-test 
HTG (n=15) PTG (n=15) CON (n=15)   HTG (n=14) PTG (n=15) CON (n=14) 
Excursion 
(cm) 
M/L 49.1 ±30.3 56.8 ± 21.6 59.1 ± 27.0 21.3 ± 9.2 55.9 ± 23.1 88.5 ± 52.1 
A/P 112.4 ± 56.2 93.4 ± 40.0 115.3 ± 51.3 48.3 ± 13.0 82.9 ± 22.4 104.9 ± 47.2 
Total 132.7 ± 69.1 120.8 ± 43.5 141.6 ± 60.6 56.4 ± 16.5 110.1 ± 34.1 158.6 ± 71.1 
 
Velocity 
(cm/sec) 
M/L 2.0 ± 1.2 2.3 ± 0.8 2.3 ± 1.0 0.8 ± 0.3 2.2 ± 0.9 3.5 ± 2.0 
A/P 4.6 ± 2.3 3.7 ± 1.5 4.6 ± 2.0 1.9 ± 0.5 3.3 ± 0.9 4.2 ± 1.9 
Total 5.4 ± 2.8 4.9 ± 1.7 4.9 ± 1.7 2.2 ± 0.6 4.4 ± 1.3 6.4 ± 2.8 
Note. M/L: medial/lateral, A/P: anterior/posterior. 
 
Individual data and p-value values were not reported by the authors; however, based on the 
reported outcomes of an ANOVA and t-test, within-group comparison before and after therapy 
demonstrated that all variables in the HTG were significantly decreased following treatment (p < 
0.05). PTG demonstrated significant differences in M/L excursion and velocity (p < 0.05), and the 
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CON demonstrated no significant differences. 
 
Table 14. Within-group comparisons, calculated by the appraisal author. Data represented as group mean ± 
standard deviation. 
Item Direction 
HTG   PTG   CON 
Mean 
Difference 
Effect 
Size   
Mean 
Difference 
Effect 
Size   Mean Difference 
Effect 
Size 
Excursion 
(cm) 
M/L 27.8 ± 19.75 0.92 
 
0.9 ± 22.35 0.04 29.4 ± 39.55 1.09 
A/P 64.1 ± 34.6 1.14 
 
10.5 ± 31.2 0.26 7.4 ± 49.25 0.14 
Total 76.3 ± 42.3 1.13 
 
10.7 ± 38.8 0.25 17 ± 57.3 0.39 
        
Velocity 
(cm/sec) 
M/L 1.2 ± 0.75 1 
 
0.1 ± 0.82 0.13 1.2 ± 1.5 1.2 
A/P 2.7 ± 1.4 1.17 
 
0.4 ± 1.2 0.27 0.4 ± 1.95 0.2 
Total 3.2 ± 1.7 1.14   0.5 ± 1.5 0.29   1.5 ± 2.25 0.88 
Note. HTG: pre-test n=15, post-test n=14. PTG: pre-test n=15, post-test n=15. 
   
The within-group effect sizes for HTG correlate with large effect sizes for all variables, suggesting 
that hippotherapy plus traditional physical therapy is a very effective treatment option to 
improve sitting balance in this population. However, analysis of the PTG demonstrated very 
small effect sizes for M/L excursion and velocity. This suggests that while statistically significant 
decreases were observed in these variables, the difference may not be clinically relevant. 
  
Between-group analysis and post-hoc testing demonstrated that excursion and velocity were 
significantly decreased in the HTG compared to PTG and CON (p < 0.05). PTG demonstrated 
significant decreases in only M/L and total excursion and velocity (p < 0.05).  
 
Table 15. Between-group comparisons, calculated by the appraisal author. Effect sizes calculated 
based on mean differences reported in Table 14. 
Item Direction 
HTG vs PTG   HTG vs CON   PTG vs CON 
Effect Size (95% CI)   Effect Size (95% CI)   Effect Size (95% CI) 
Excursion 
(cm) 
M/L 1.27 (0.47 - 2.07) 0.05 (-0.69 - 0.79) 0.90 (0.13 - 1.66) 
A/P 1.63 (0.79 - 2.47) 1.33 (0.51 - 2.15) 0.08 (-0.65 - 0.80) 
Total 1.62 (0.78 - 2.46) 1.18 (0.38 - 1.98) 0.13 (-0.60 - 0.86) 
Velocity 
(cm/sec) 
M/L 1.40 (0.59 - 2.21) 0.00 (-0.74 - 0.74) 0.92 (0.15 - 1.69) 
A/P 1.77 (0.91 - 2.63) 1.35 (0.53 - 2.18) 0.00 (-0.73 - 0.73) 
Total 1.13 (0.34 - 1.91) 0.85 (0.08 - 1.63)   0.53 (-0.21 - 1.27) 
 
Regarding HTG vs PTG, large effect sizes were observed in all variables except total velocity. In 
addition, 95% confidence intervals do not cross zero for any measures. Regarding HTG vs CON, 
all variables demonstrated large effect sizes and 95% confidence intervals except M/L excursion 
and M/L velocity, however, on average these effect sizes are not as large as HTG vs PTG, which is 
likely due to significantly larger confidence intervals that also cross zero on multiple occasions. 
Regarding PTG vs CON, M/L excursion and velocity demonstrated large effect sizes. All other 
variables demonstrate small or medium effect sizes, however the confidence intervals cross 
zero. 
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The results of this study demonstrate that while PTG had within-group improvement in sitting 
balance from baseline to post-treatment, as well as significant improvements as compared to 
control, HTG also experienced significant improvements and large effect sizes in both within- 
and between-group comparisons to both PTG and CON (effect sizes range: 0.37 - 2.66; p < 0.05). 
This suggests that HTG (hippotherapy plus traditional physical therapy) is more effective than 
physical therapy alone and no treatment to improve sitting balance in children, ages 6-10 years, 
with spastic hemiplegic and diplegic CP. 
 
Applicability of study results: 
 
Benefits vs. Costs: Following the completion of the study appraisal, few benefits were identified. 
Time commitment for the therapist, patient, and family was low as treatment sessions were 30 
minutes in duration, performed semi-weekly for eight weeks. While not directly addressed by 
the study authors, financial costs also appear relatively low as no additional equipment was 
required for treatment other than access to the equestrian team.  The results of the study also 
suggest that, despite a low time and financial commitment, hippotherapy appears to be an 
effective treatment option for this population, further justifying these benefits. 
 
Access to a certified hippotherapy center or equestrian team is a large cost for this type of 
treatment, as mentioned previously. In addition, while the HTG and PTG received the same 
number of treatment sessions, total treatment time appears to be different as both groups 
received a 30-minute session of physical therapy outside of the hippotherapy component of the 
HTG. It is also not readily apparent if CON received any direct time with the therapists 
throughout this study. In addition, extra training is required of the therapists to become 
educated in hippotherapy treatment. 
 
Feasibility of treatment: The procedures and experimental parameters utilized in this study are 
not described well enough for reproduction. Details of exercises provided during the 
hippotherapy sessions and physical therapy sessions are not provided, and it is not clear what 
intervention, if any, was received by CON. While requirements of clinician expertise and time 
commitment are what would likely be available in a PT setting, ease of locating a certified 
hippotherapy center presents a large barrier to prevent clinicians from utilizing hippotherapy. 
The number and duration of PT sessions in this study are within the realm of that allowed by 
insurance companies, however, and an HEP was not required. Treatment was feasible for the 
patients as well, as treatment was not painful, no adverse events were reported, and the data 
suggests that hippotherapy in conjunction with physical therapy is an effective treatment option 
for this population. 
 
Summary of external validity: This study most accurately matches the patient age, primary 
diagnosis, both length and type of intervention, and typical population seen in a school district 
for children with CP. In addition, this study utilizes the treatment intervention schedule that is 
most relevant to the clinical scenario by comparing hippotherapy plus physical therapy to 
physical therapy alone and control. However, the number of major threats to internal validity 
compromise the ability to generalize results to a larger population.  
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Article: Casady RL & Nichols-Larsen DS. The effect of hippotherapy on ten children with cerebral 
palsy. Pediatric Physical Therapy, 2004; 165-172. 
 
Clinical Bottom Line: Based on the results of this article, hippotherapy appears to be an 
effective and safe treatment option to improve gross motor function in children age 2-7 years 
with a primary diagnosis of CP. However, eight major threats to internal validity were identified, 
which, despite adequate feasibility of treatment, dramatically reduce confidence in and 
generalizability of the results. This study utilized an A-B-A design where all ten children received 
45-minute hippotherapy treatment sessions once per week for ten weeks. Analysis with 
analysis-of-variance (ANOVA) and a Tukey post-hoc test for honest significant difference (HSD) 
demonstrated a significant improvement in the crawling/kneeling dimension (mean difference = 
2.85, HSD = 2.64), and the total GMFM-88 score (mean difference = 12.35, HSD = 9.34). While 
hippotherapy appears to be an effective and timely intervention, internal and external validity 
issues suggest further research is necessary to reach a decision regarding the clinical PICO, 
which should include a strict treatment and study protocol and design and a larger sample size. 
 
Article PICO: 
 
 Population— 11 children with a primary diagnosis of CP, age 2.3-6.8 years. 
 
 Intervention— Hippotherapy 
 
 Comparison— Baseline GMFM measurements 
 
 Outcomes— PEDI and GMFM 
 
Blinding: As the authors utilized an A-B-A design where the subjects served as their own control, 
blinding of the subjects, therapists, and assessors was not possible. This, however, is not a 
significant threat as the children likely were not able to manipulate their performance to 
influence the results of the study. In addition, as there was no true comparison group, therapist 
administration of the treatment and assessor evaluation of the treatment effect would not have 
a significant effect on the study outcome. 
 
Controls: There was no true control group in this study and the 11 subjects served as their own 
control. This was not an appropriate comparison group because the observed differences 
between groups cannot be attributed to the intervention as there is a large risk of maturation 
due to the long time periods between assessment sessions and overall 30-week study duration.  
 
Randomization: Due to study design, randomization was not possible. To establish the study 
sample, the authors utilized convenience sampling via physician and therapist recruiting of 
appropriate subjects. 
 
Study: This study utilized a single-subject, A-B-A design and was conducted at an NARHA (now 
PATHI) therapeutic riding center under the supervision of a physical therapist with 18 years of 
practical experience and certification in hippotherapy and a NAHRA-registered therapeutic 
riding instructor. Study authors obtained a convenience sample by contacting local physicians 
and therapists and to identify eleven subjects who were appropriate for the study. Inclusion and 
exclusion criteria were as follows: primary diagnosis of CP and have never had hippotherapy 
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treatment. Subjects were also required to obtain medical clearance to ride a horse and a referral 
for physical therapy from their primary physician. Any concurrent events that may have affected 
development and study outcomes were reported by the parent. 
 
A time-series, quasi-experimental research design was utilized to show trends in development 
over a 30-week period. Four testing dates were implemented at which time all outcome 
measures were assessed. These testing dates are as follows: pre-test 1 (T1), pre-test 2 (T2), post-
test 1 (T3), and post-test 2 (T4), and a 10-week time interval between test dates was held 
constant. Following T2, the treatment phase began, and concluded with T3. Figure 2 provides a 
graphic representation of the treatment and assessment scheme. All eleven subjects received 
one weekly session of hippotherapy during the treatment period. 
 
Figure 2. Assessment intervals. 
T1 
Pre-treatment 
T2 
Treatment 
T3 
Post-treatment 
T4 
10 weeks 10 weeks 10 weeks 
 
Assessment of subjects was completed via a videotape review. Subjects were recorded on each 
test date while performing the items on the GMFM that were appropriate to their current skill 
level. These recordings were later watched and rated by two scorers who had no contact with 
one another during the study. One scorer was a PT with 26 years of pediatric experience; the 
other was an OT with 20 years of pediatric experience. Reliability was established between the 
two scorers using videotapes of three children who did not participate in the study performing 
the GMFM test items. Previous research has demonstrated reliability values ranging from 0.77-
0.88 using videotaped assessments viewed by therapists with no previous GMFM experience6. 
The average absolute agreement between the two scorers was 94.6% and interrater reliability 
was excellent (ICC[3,1] = 0.990-0.999). 
 
Individual hippotherapy appointments were 45 minutes in length, although the authors state 
that the actual amount of time on the horse was typically 20-30 minutes. The physical therapists 
selected the appropriate horse for each subject and the horses typically worked during sessions 
with an experienced horse handler walking behind the horse. The physical therapist and a 
volunteer side walker walked along either side of the horse to assist the subjects with postural 
control as necessary, including initially riding tandem with the subjects. The horse's movement 
was modified during treatment sessions depending on the needs and responses of the subject, 
which included direction to walk, halt, alter tempo, or change the pattern of the horse's 
movement. While the horse walked, subjects were instructed to maintain postural alignment 
and symmetry of the head, trunk, and lower extremities with as little assistance as possible. If 
necessary, a U-shaped pillow was placed around the waist of subjects in the event that external 
support was needed. 
   
Outcome measures: The outcome measures used in this study were the PEDI and GMFM-88; 
however, the only outcome measure of interest to help answer the clinical question is the 
GMFM-88. Clinimetric characteristics of this measure are as previously discussed. The reported 
MCID of 0.8 was calculated using ambulatory children16. However, as the patient of interest was 
not ambulatory prior to the introduction of hippotherapy and 60% of the subjects in this study 
were non-ambulatory, this MCID will not be used for data analysis.   
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Study losses: This study experienced a loss of one subject, which occurred prior to T2 and it is 
not clear why this loss occurred. An intention-to-treat analysis was not indicated. 
 
Summary of internal validity: Eight major threats were identified in this study, reducing 
confidence in the authors’ findings. The first two threats are related to lack of blinding, the first 
being the Hawthorne Effect. Without subject blinding, repeated testing and observation with a 
video camera, and introduction of a new therapy intervention, the subjects may behave 
differently when they know they are being studied. Rater bias is also a major threat as a lack of 
assessor blinding may result in a subconscious tendency to rate the subjects higher on the 
GMFM-88 as the study progresses, thus inappropriately influencing study results.  
 
Threats also exist because of the procedures used by the authors for subject recruitment and 
group assignment. Without the inclusion of a control group, the threat of maturation exists.   As 
CP is a non-progressive disorder and the study duration was 30-weeks in length, there is the 
possibility that changes in GMFM-88 scores seen at T3 and T4 may be due to natural history of 
the disorder rather than the intervention. Also, because the authors utilized convenience 
sampling to locate appropriate subjects for the study, a selection bias threat is introduced and 
the study sample may not be heterogeneous nor be an accurate representation of children with 
CP as a whole, which dramatically affects the external validity of the results. Furthermore, 
inadequate power is a threat. With a small sample size and no power analysis performed, either 
a Type 1 or Type II error may exist.  
 
The final three threats relate to the study procedures carried out by the authors.  Children in 
this study were assessed four times throughout the study and, as a result, may have become 
familiar with the testing procedures for the GMFM-88, leading to improved scores independent 
of treatment effect. Because CP can present with or without cognitive impairments, this is a 
major threat. The authors also did not control for extraneous variables. Because concurrent 
events were not restricted during the study duration, some subjects continued to receive 
standard physical, occupational, and/or speech and language therapy. In addition, one subject 
failed to wear a new AFO, another began oral baclofen during pre-treatment, another had 
bilateral otitis media during treatment, and others needed to be treated with hyperbaric oxygen 
during various phases of the study. This is a major threat because these events, particularly the 
continued therapy for some subjects, could lead to changes in GMFM-88 scores independent of 
treatment effects related to the hippotherapy. The final threat to internal validity is the lack of a 
strict treatment protocol. Because hippotherapy treatment was not standardized across the 
sample, there is the possibility that improvements in GMFM-88 scores seen at T3 and T4 may be 
due to individually tailored treatment sessions rather than hippotherapy treatment effect. 
Overall, this study has poor internal validity, dramatically decreasing confidence in study results. 
  
Evidence: The outcome measure that is applicable to the clinical scenario is the GMFM-88. As a 
result, data and calculations discussed in this section will only analyze the GMFM-88 scores. The 
authors do not report individual or group mean data at each assessment period, therefore all 
reported statistical analysis was conducted by the study authors. Effects of hippotherapy were 
analyzed with an ANOVA, and the results are represented in Table 16.  
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Table 16. Results of GMFM-88 ANOVA, calculated by study authors.  
GMFM Dimension df F p-value  
Lying/rolling 1.26 3.47 0.082  
Sitting 1.34 10.99 0.004*  
Crawling/kneeling 1.75 18.21 < 0.000*  
Standing 1.36 12.05 0.003*  
Walk/run/jump 1.07 6.69 0.027*  
Total 1.26 32.62 < 0.000*  
Note. Significance value set at p < 0.05; * denotes statistically significant difference. 
   
ANOVA demonstrated that four of the five dimensions (sitting, crawling/kneeling, standing, and 
walk/run/jump) in the GMFM-88, as well as the total GMFM-88 score, demonstrated a 
significant change in score, as represented by a p-value < 0.05. Because this analysis includes 
change in three different phases of the study, the study authors conducted a Tukey post-hoc 
test to determine in which phases these significant differences occur. A Tukey HSD was 
calculated for each dimension of and the total GMFM-88 scores, and results are represented in 
Table 17. 
 
Table 17. Results of Tukey post-hoc test. 
GMFM Dimension Tukey HSD 
Mean Difference 
T1-T2 T2-T3 T3-T4 
Lying/rolling -- -- -- -- 
Sitting 3.76 2.85 3.20 1.15 
Crawling/kneeling 2.64 2.35 2.85* 1.55 
Standing 1.99 1.20 1.65 1.25 
Walk/run/jump 4.98 1.95 2.80 2.90 
Total 9.34 9.00 12.35* 8.25 
Note. * denotes statistically significant difference relative to Tukey HSD. Data unavailable 
for lying/rolling due to p > 0.05. 
 
Following the Tukey post-hoc test, a significant difference was found in the crawling/kneeling 
dimension and the total GMFM-88 score, represented by a mean difference of greater value 
than the calculated Tukey HSD. This suggests that hippotherapy yielded a significant change in 
gross motor function for children with a primary diagnosis of CP. The mean difference of T1-T2 
did not exceed the Tukey HSD, suggesting no significant change in baseline assessments prior to 
the introduction of hippotherapy. Additionally, the mean difference of T3-T4 did not exceed the 
Tukey HSD, suggesting that improvements in gross motor function were maintained following 
cessation of treatment with hippotherapy. 
 
Applicability of study results: 
 
Benefits vs. Costs: Following completion of the study appraisal, a number of benefits were 
identified. Time commitment for the therapist, patient, and family was low as treatment 
sessions were 30 minutes in duration and performed one time per week for ten weeks. An HEP 
is not required for this type of treatment. While not directly addressed by the study authors, 
financial costs also appear relatively low as no additional equipment was required for treatment 
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other than access to a certified hippotherapy center. Additionally, no adverse events were 
reported. Based on the results of this study, these benefits are justified as hippotherapy appears 
to be an effective treatment option for this population. 
 
Access to a certified hippotherapy center and equestrian team is a large cost for this type of 
treatment due to potential transportation costs and general access, as discussed previously. 
Additional training is also required of the therapists to become educated in hippotherapy 
treatment.  
 
Feasibility of treatment: The procedures and experimental parameters utilized in this study are 
not described well enough for reproduction. Details of treatment session protocol are not 
provided as treatment appears to have been individualized. This number and duration of 
treatment sessions is well within what is typically covered by insurance companies, especially 
for children who typically receive treatment in a school district setting. Additionally, the 
treatment appears to be feasible for patients as a home exercise program is not required for 
benefits to be attained, treatment was not painful, and no adverse events were reported. 
However, because this study was conducted at an external hippotherapy center, there is the 
potential that children must be taken out of school to attend treatment sessions, depending on 
hours of operation of the hippotherapy center and therapist availability. 
 
Summary of external validity: This study accurately matches the patient age, primary diagnosis, 
length and type of intervention, and a typical population seen in a school district. In addition, 
the subjects in the study presented with a variety of types of CP, which are discussed previously. 
However, the large number of major threats to internal validity and lack of a sufficiently 
described treatment protocol greatly compromise the ability to generalize results to a larger 
population. 
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Synthesis/Discussion: The purpose of this critically appraised topic was to compare the efficacy 
of hippotherapy as a treatment option for children with a primary diagnosis of cerebral palsy to 
'traditional' physical therapy consisting of stretching and strengthening exercises using the 
highest quality available research.  
 
The PEDro scores for these chosen studies ranged from 8/10 to 3/10. PEDro scores rated above 
5/10 are considered to have moderate to high quality research design as reported by the PEDro 
database. Two articles met this criterion. However, the PEDro score for McGibbon et al. was 
reported by the database with a score of 7/10, but this score does not apply to the entirety of 
the study, as discussed in the individual article appraisal. 
 
Based on the four studies located that address this topic, there is relatively consistent evidence 
supporting the use of hippotherapy as an intervention for children with CP. While Hererro et al. 
demonstrated that a hippotherapy simulator does not provide statistically or clinically 
meaningful improvements in gross motor function for this population, McGibbon et al., Kang et 
al., and Casady et al. found that hippotherapy is an effective means to improve gross motor 
function. This discrepancy in outcomes is likely due to the treatment effect being studied and 
multiple methodological flaws. Additionally, only McGibbon et al. assessed hippotherapy plus 
traditional physical therapy compared to physical therapy alone, which most accurately matches 
the clinical scenario. However, due to multiple study design and major internal validity threats, 
the ability to draw meaningful conclusions from all four articles is very limited.  
 
Notable methodological flaws are as follows. None of the four articles utilized blinding of the 
subjects or therapists, and Kang et al. and Casady et al. did not blind assessors. These are major 
threats to internal validity because of the potential subconscious tendency to not only rate 
subjects higher on outcome measures in a manner that supports the hypothesis but also to 
provide treatment interventions that bias the experimental group. McGibbon et al. and Casady 
et al. also utilized an A-B and A-B-A study design, respectively. The lack of a true control group in 
these studies, combined with the lack of a strict treatment protocol, limits the ability to 
conclude that observed treatment effects were actually due to the intervention. Additionally, 
McGibbon et al. utilized inappropriate statistical testing, as the manner in which data was 
collected violates the inherent assumptions of score data tests (i.e. t-test or ANOVA). As a result, 
the appraisal author converted data to rank order data and was assessed with a Friedman test. 
This discrepancy further limits the ability to draw meaningful conclusions from the reported 
results. 
 
Other differences between studies were apparent, including the lack of a long-term follow-up by 
Hererro et al. As the clinical scenario necessitates the identification of long-term effects of 
hippotherapy, this limits the external validity of the study. Additionally, McGibbon et al., 
Hererro et al., and Casady et al. did not utilize a power analysis prior to any data collection, 
which suggests the sample size may be too small and could result in a Type I or Type II error. 
This further limits the ability to draw meaningful conclusions from the results as a more 
appropriate sample size may yield different results. Finally, Kang et al. did not utilize an outcome 
measure that directly addresses gross motor function. However, as one dimension of the 
GMFM-66 and -88 addresses sitting balance, postural sway excursion and velocity as measured 
by a force plate appears to have face validity, is sensitive in discernment of balance performance 
in this population21-24, and would theoretically correlate with findings on the GMFM. 
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In conclusion, while it appears that hippotherapy is an effective and timely intervention to 
improve gross motor function for children with cerebral palsy, poor study design and multiple 
methodological flaws suggest that further high quality research is necessary to reach a definitive 
conclusion regarding the clinical PICO. 
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